IL117249A - Vaccine compositions comprising hepatitis B antigen 3-O-deacylated monophosphoryl lipid A and aluminum phosphate - Google Patents

Vaccine compositions comprising hepatitis B antigen 3-O-deacylated monophosphoryl lipid A and aluminum phosphate

Info

Publication number
IL117249A
IL117249A IL11724996A IL11724996A IL117249A IL 117249 A IL117249 A IL 117249A IL 11724996 A IL11724996 A IL 11724996A IL 11724996 A IL11724996 A IL 11724996A IL 117249 A IL117249 A IL 117249A
Authority
IL
Israel
Prior art keywords
hepatitis
antigen
aluminum phosphate
vaccine compositions
monophosphoryl lipid
Prior art date
Application number
IL11724996A
Other languages
English (en)
Other versions
IL117249A0 (en
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL117249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL117249A0 publication Critical patent/IL117249A0/xx
Publication of IL117249A publication Critical patent/IL117249A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11724996A 1995-02-25 1996-02-23 Vaccine compositions comprising hepatitis B antigen 3-O-deacylated monophosphoryl lipid A and aluminum phosphate IL117249A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions

Publications (2)

Publication Number Publication Date
IL117249A0 IL117249A0 (en) 1996-06-18
IL117249A true IL117249A (en) 2000-11-21

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11724996A IL117249A (en) 1995-02-25 1996-02-23 Vaccine compositions comprising hepatitis B antigen 3-O-deacylated monophosphoryl lipid A and aluminum phosphate

Country Status (35)

Country Link
US (1) US5972346A (cs)
EP (1) EP0810877B1 (cs)
JP (1) JP3881015B2 (cs)
KR (1) KR100365373B1 (cs)
CN (1) CN1101225C (cs)
AP (1) AP766A (cs)
AR (1) AR002279A1 (cs)
AT (1) ATE209045T1 (cs)
AU (1) AU695921B2 (cs)
BG (1) BG101851A (cs)
BR (1) BR9607458A (cs)
CA (1) CA2212552C (cs)
CZ (1) CZ288417B6 (cs)
DE (1) DE69617211T2 (cs)
DK (1) DK0810877T3 (cs)
EA (1) EA199700126A1 (cs)
ES (1) ES2166879T3 (cs)
FI (1) FI118118B (cs)
GB (1) GB9503863D0 (cs)
HU (1) HU224832B1 (cs)
IL (1) IL117249A (cs)
MA (1) MA23814A1 (cs)
MX (1) MX9706450A (cs)
MY (1) MY113428A (cs)
NO (1) NO319394B1 (cs)
NZ (1) NZ302674A (cs)
OA (1) OA10612A (cs)
PL (1) PL182679B1 (cs)
PT (1) PT810877E (cs)
SA (1) SA96160633B1 (cs)
SK (1) SK115097A3 (cs)
TR (1) TR199700849T1 (cs)
TW (1) TW467745B (cs)
WO (1) WO1996026741A1 (cs)
ZA (1) ZA961460B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CA2355680A1 (en) * 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2006215419B2 (en) * 2005-02-16 2012-03-08 Novartis Vaccines And Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3D-MPL
BRPI0614254A2 (pt) * 2005-08-02 2011-03-15 Novartis Vaccines & Diagnostic redução de interferência entre adjuvantes contendo óleo e antìgenos contendo tensoativos
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
WO2020099927A1 (en) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0414374T3 (da) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
CA2109714A1 (en) * 1991-05-29 1992-12-10 Frederic H. Moll Retraction apparatus and methods for endoscopic surgery
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
KR100310510B1 (ko) * 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
SA96160633B1 (ar) 2005-10-15
PL321966A1 (en) 1998-01-05
DK0810877T3 (da) 2002-02-25
HK1004117A1 (en) 1998-11-20
MY113428A (en) 2002-02-28
CZ267497A3 (cs) 1998-02-18
NZ302674A (en) 1999-01-28
DE69617211D1 (en) 2002-01-03
CZ288417B6 (en) 2001-06-13
TW467745B (en) 2001-12-11
OA10612A (en) 2002-08-29
PL182679B1 (pl) 2002-02-28
DE69617211T2 (de) 2002-07-25
JPH11501018A (ja) 1999-01-26
IL117249A0 (en) 1996-06-18
HU224832B1 (en) 2006-03-28
BG101851A (en) 1998-04-30
FI973457A0 (fi) 1997-08-22
GB9503863D0 (en) 1995-04-19
SK115097A3 (en) 1998-02-04
ZA961460B (en) 1996-08-29
CN1101225C (zh) 2003-02-12
AP9701060A0 (en) 1997-10-31
FI973457L (fi) 1997-08-22
NO319394B1 (no) 2005-08-08
BR9607458A (pt) 1998-06-30
AR002279A1 (es) 1998-03-11
EP0810877B1 (en) 2001-11-21
HUP9801242A3 (en) 2000-08-28
MA23814A1 (fr) 1996-10-01
ATE209045T1 (de) 2001-12-15
US5972346A (en) 1999-10-26
TR199700849T1 (xx) 1998-01-21
CN1176604A (zh) 1998-03-18
EA199700126A1 (ru) 1998-02-26
PT810877E (pt) 2002-04-29
EP0810877A1 (en) 1997-12-10
KR100365373B1 (ko) 2003-07-07
AP766A (en) 1999-09-17
WO1996026741A1 (en) 1996-09-06
CA2212552A1 (en) 1996-09-06
MX9706450A (es) 1998-07-31
NO973873L (no) 1997-08-22
HUP9801242A1 (hu) 1998-08-28
AU695921B2 (en) 1998-08-27
ES2166879T3 (es) 2002-05-01
AU4878096A (en) 1996-09-18
JP3881015B2 (ja) 2007-02-14
NO973873D0 (no) 1997-08-22
FI118118B (fi) 2007-07-13
CA2212552C (en) 2006-07-11
KR19980702480A (ko) 1998-07-15

Similar Documents

Publication Publication Date Title
NZ302674A (en) Hepatitis b vaccine with hepatitis b antigen, 3-o-deacylated monophosphoryl lipid a, and aluminium phosphate
HU9402758D0 (en) Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a
FI954514L (fi) 3-O-deasyloitua monofosforyylilipidiä A sisältävä rokotekoostumus
EG25924A (en) A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
AU1648097A (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
IL122589A0 (en) Vaccines against hepatitis c
AU1308495A (en) Influenza vaccine
IL108681A0 (en) Influenza vaccine compositions
IL115197A0 (en) Vaccine preparations
AU2971692A (en) Flystrike antigen and vaccine and method for preparation
GB9526433D0 (en) Vaccine component
ZA965274B (en) A vaccine comprising a polysaccharide-antigen conjugate from haemophilus influenzae type b adsorbed onto aluminium phosphate and its use in combination vaccines
AU3931197A (en) Vaccines and antigenic conjugates
GB9524214D0 (en) Methods and compositions for hiv vaccination
ZA964016B (en) Bacterial antigens and vaccine compositions
SI0810877T1 (en) Hepatitis b vaccine
IL94510A0 (en) Influenza vaccine
GB9526438D0 (en) Vaccine component

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees